New cancer drug enters first human testing
NCT ID NCT07387068
Summary
This is the first human trial testing a new antibody called GEN1079 for people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to find safe doses and see if the treatment shows early signs of helping control cancer. About 121 participants with specific advanced cancers will receive the drug and be monitored for side effects and tumor response over approximately 33 to 67 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START Midwest, LLC
RECRUITINGGrand Rapids, Michigan, 49546, United States
Conditions
Explore the condition pages connected to this study.